Tuesday, September 13, 2016

BRIEF-Aptinyx receives FDA fast track designation for development of NYX-2925

* Aptinyx receives FDA fast track designation for

development of NYX-2925 as treatment for neuropathic pain

associated with diabetic peripheral neuropathy

Source text for Eikon:

Further company coverage: [Aptinyx inc]

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)